/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Novartis has completed patient enrollment of the pivotal Phase 3 Lp(a) HORIZON.
CARLSBAD, Calif., Nov. 24, 2021 /PRNewswire/ Ionis Pharmaceuticals, Inc. today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-LRx.. | November 24, 2021
/PRNewswire/ Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly.
/PRNewswire/ Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the initiation of CORE, the second Phase 3.
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.